Skip to main content
. 2019 Mar 21;8(4):1389–1400. doi: 10.1002/cam4.1970

Figure 3.

Figure 3

A, Comparison of adverse events in fulvestrant‐palbociclib group and letrozole‐palbociclib group. B, Unexpected treatment changes due to side effects